RxDoctor Payments Data

Alicia Devore, APRN

Family · Westerville, OHNPI 1467687384

Payments from drug & device makers

$660in general payments, 2019–2025

Across 32 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$90
  • Novartis$68
  • Neurocrine Biosciences, Inc.$60
  • Abbott$56
  • Novo Nordisk$48
  • BETA Bionics, Inc.$45
  • plus $294 from 12 others

What the payments were for

  • Food & beverage$660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$660 in reported general payments places this provider in the 60th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$41,830
Medicare patients
236
Services billed
799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide285$333,101
MounjaroTirzepatide263$308,391
JardianceEmpagliflozin183$172,395
TrulicityDulaglutide117$126,663
Tresiba Flextouch U-200Insulin Degludec78$99,548
Humalog Kwikpen U-200Insulin Lispro40$82,804
Tresiba Flextouch U-100Insulin Degludec132$80,273
Humulin R U-500 KwikpenInsulin Regular, Human29$60,795
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog35$44,551
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/755$43,658
FarxigaDapagliflozin Propanediol33$37,856
Fiasp FlextouchInsulin Aspart (Niacinamide)40$33,942
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog27$27,651
Humalog Kwikpen U-100Insulin Lispro48$20,443
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog42$17,675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp, Novolog$48$354,058322 claims
Boehringer IngelheimJardiance$37$172,395183 claims
AstraZenecaFarxiga$17$37,85633 claims
AbbVieSynthroid$16$1,82321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,812 family providers in Ohio.

Other family in Westerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →